The Frazier Life Sciences team invests in and builds companies developing and commercializing novel therapeutics.
Passage Bio Launches with $115.5 Million Series A to Develop AAV-Delivered Therapeutics to Treat Rare Monogenic CNS Diseases
Frazier Healthcare Partners Launches Recida Therapeutics to Develop Novel Therapeutics for Serious Antibiotic-Resistant Infections
Amunix Announces Licensing Agreement with Merck for ProTIA Immune Activator Platform
Mirum Pharmaceuticals Secures $120 Million in Series A Financing to Develop Phase 3-Ready Maralixibat for Rare Liver Diseases